SCHEDULE: Venrock Entities Disclose 9.9% Stake in Korsana Biosciences

Several Venrock-affiliated entities and individuals have jointly filed a Schedule 13D, disclosing beneficial ownership of 9.9% of Korsana Biosciences, Inc. common stock following a merger.

Summary

• Multiple Venrock-affiliated entities and individuals, collectively referred to as the Reporting Persons, have filed a Schedule 13D regarding their beneficial ownership of Korsana Biosciences, Inc. (formerly Cyclerion Therapeutics, Inc.).
• The filing follows the completion of a merger between Korsana Biosciences, Inc. and an entity formerly known as Cyclerion Therapeutics, Inc. on September 8, 2026.
• The Reporting Persons collectively purchased an aggregate of 10,000,000 shares of Series Seed preferred stock, 37,871,909 shares of Series A preferred stock, 21,936,295 shares of common stock, and pre-funded warrants to purchase 15,935,614 shares of common stock from the former Korsana Biosciences, Inc. for a total of $134,843,200.
• Following the merger and conversion, the Reporting Persons beneficially own 4,552,277 shares of Korsana Biosciences, Inc. common stock, representing 9.9% of the outstanding shares.
• The securities were purchased for investment purposes with the aim of increasing the value of their investments and the Issuer.
• Nimish Shah and Andrew Gottesdiener, partners at Venrock, are members of the Korsana Biosciences, Inc. board of directors.
• Certain restrictions, known as Beneficial Ownership Blockers, limit the conversion of Series B Preferred stock and exercise of Pre-Funded Warrants to maintain ownership below 9.99%.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, primarily indicating a change in reporting structure and a significant investment stake, rather than immediate operational news.

Positives

• Significant investment stake (9.9%) in Korsana Biosciences, Inc. by experienced venture capital entities.
• The Reporting Persons have a stated investment purpose, aiming to increase the value of their holdings and the Issuer.
• Representation on the board of directors through Nimish Shah and Andrew Gottesdiener, indicating potential influence and oversight.
• The merger transaction has been completed, providing a new corporate structure for Korsana Biosciences, Inc.

Negatives

• The Beneficial Ownership Blockers on Series B Preferred stock and Pre-Funded Warrants currently restrict further conversion or exercise, capping ownership at 9.99%.
• The filing is primarily a disclosure of ownership and investment intent, with no immediate operational updates or performance metrics for Korsana Biosciences, Inc.

Risks

• Potential for future stock sales by the Reporting Persons, depending on their evaluation of the Issuer's business and market conditions.
• The Beneficial Ownership Blockers could prevent the Reporting Persons from increasing their stake beyond 9.99% without triggering conversion/exercise limitations.
• The Reporting Persons reserve the right to change their investment intent, which could lead to divestment or further acquisition of securities.

Future Outlook

The Reporting Persons intend to hold their investment for the purpose of increasing the value of their investments and the Issuer. They may purchase additional securities, depending on their evaluation of the Issuer's business, prospects, and market conditions. They also reserve the right to dispose of their securities at any time. There is no specific forward-looking guidance provided regarding the Issuer's financial performance.

Management Comments

• The Reporting Persons purchased securities for investment purposes with the aim of increasing the value of their investments and the Issuer.
• Each of the Reporting Persons reserves the right to increase or decrease its holdings on such terms and at such times as each may decide.
• Each of the Reporting Persons reserves the right to propose or participate in future transactions which may result in one or more of such actions, including but not limited to, an extraordinary corporate transaction, such as a merger, reorganization or liquidation, sale of a material amount of assets of the Issuer or its subsidiaries, or other transactions which might have the effect of causing the common stock to become eligible for termination of registration under Section 12(g) of the Act.
• The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of the undersigned, is not assuming, nor is Venrock assuming, any of the undersigneds responsibilities to comply with the Exchange Act, including without limitation Sections 13 and 16 of the Exchange Act.

Industry Context

StockSavvy.ai notes that this filing reflects a common post-merger scenario where significant pre-merger investors transition to a public company reporting structure. The 9.9% stake is typical for venture capital firms seeking substantial influence without triggering mandatory control disclosures or regulatory hurdles associated with higher ownership percentages.

Corporate Governance

Stakeholder Impact

• Shareholders: The disclosure of a significant 9.9% stake by Venrock entities provides transparency on major ownership. Potential future actions by these entities could influence share price.
• Management and Board: The presence of Venrock partners on the board suggests a strong alignment of interests and potential for strategic guidance.
• Creditors/Suppliers: No direct impact indicated in this filing.

Next Steps

• The Reporting Persons may purchase additional securities of the Issuer.
• The Reporting Persons may dispose of all or a portion of their securities.
• The Reporting Persons may propose or participate in future corporate transactions.
• The Power of Attorney remains in effect until the undersigned is no longer required to file, revokes it, or the attorney-in-fact is no longer employed by Venrock.

Key Dates

Keywords

Schedule 13D, Korsana Biosciences, Venrock, Merger, Beneficial Ownership, Venture Capital, Investment, Securities